SEARCH

SEARCH BY CITATION

References

  • 1
    World Health Organization. 2013 Dengue guidelines for diagnosis, treatment, prevention and control. [Cited September 18, 2013.] Available from: http://www.who.int/rpc/guidelines/9789241547871/en/
  • 2
    Halstead S.B. ( 2007) Dengue. Lancet 370: 164452.
  • 3
    Heinz F.X., Stiasny K. ( 2012) Flavivirus and flavivirus vaccines. Vaccine 30: 43016.
  • 4
    Halstead S.B., Vaughn D.W. ( 2008) Dengue vaccines. In: Plotkin S.A. , Orenstein P.A., eds. Vaccines. Maryland Heights: Saunders Elseviers, pp. 115661.
  • 5
    Murphy B.R., Whitehead S.S. ( 2011) Immune response to dengue virus and prospect for a vaccine. Annu Rev Immunol 29: 587619.
  • 6
    Schmitz J., Roehrig J., Barret A., Hombach J. ( 2011) Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine 29: 727684.
  • 7
    van der Schaar H.M., Wilschut H.M., Smit J.C. ( 2009) Role of antibodies in controlling dengue virus infection. Immunobiology 214: 61329.
  • 8
    Halstead S.B. ( 2003) Neutralization and antibody dependent enhancement of dengue viruses. Adv Virus Res 60: 42167.
  • 9
    Pierson T.C., Xu Q., Nelson S., Oliphant T., Nybakken G.E., Freemont D.H., Diamond M.S. ( 2007) The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1: 13544.
  • 10
    Gubler D.J., Kuno G., Markoff L. ( 2007) Flavivirus. In: Knipe D.M. , Howley P.M., eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins, pp. 115322.
  • 11
    Kuhn R.J., Zhang W., Rossman M.G., Pletnev S.V., Corver J., Lenches E., Mukhopadhyay S., Chipman P.R., Strauss E.G., Baker T.S., Strauss J.H. ( 2002) Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108: 71725.
  • 12
    Modis Y., Ogata S., Clements D., Harrison S.C. ( 2003) A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 100: 698691.
  • 13
    Rey F.A. ( 2003) Dengue virus envelope glycoprotein structure: new insight into its interactions during viral entry. Proc Natl Acad Sci USA 100: 6899901.
  • 14
    Modis Y., Ogata S., Clements D., Harrison S.C. ( 2005) Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 79: 122331.
  • 15
    Modis Y., Ogata S., Clements D., Harrison S.C. ( 2004) Structure of the dengue virus envelope protein after membrane fusion. Nature 427: 31319.
  • 16
    Volk D.E., Lee Y.C., Li X., Thiviyanathan V., Gromowski G.D., Li L., Lamb A.R., Beasley D.W., Barrett A.D., Gorenstein D.G. ( 2007) Solution structure of the envelope protein domain III of dengue-4 virus. Virology 364: 14754.
  • 17
    Beltramello M., Williams K.L., Simmons C.P., Macagno A., Simonelli L., Quyen N.T., Sukulpovi-Petty S., Navarro-Sanchez E., Young P.R., de Silva A.M., Rey F.A., Varani L., Whitehead S.S., Diamond M.S., Harris E., Lanzavecchia A., Sallusto F. ( 2010) The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8: 27183.
  • 18
    Wahala W.M., Krauss A.A., Haymore L.B., Accavitti Loper M.A., Baric R.S., de Silva A.M. ( 2009) Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392: 10313.
  • 19
    Williams K.L., Wahala M.B.P., Orozco S., de Silva A.M., Harriss E. ( 2012) Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 429: 1220.
  • 20
    Chambers T.J., Nestorowicz A., Mason P.W., Rice C.M. ( 1999) Yellow fever/Japanese encephalitis chimeric viruses: construction, and biological properties. J Virol 73: 3095101.
  • 21
    Chambers T.J., Jiang Y., Droll D.A., Schleisinger J.J., Davidson A.D., Wright P.J., Jiang X. ( 2003) Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model. J Virol 77: 365568.
  • 22
    Mathenge E.G.M., Parquet M.C., Fukanoshi Y., Houhara S., Wong P.F., Ichinose A., Hasebe F., Inoue S., Morita K. ( 2004) Fusion PCR generated Japanese encephalitis virus/dengue 4 virus chimera exhibits lack of neuroinvasiveness, attenuated neurovirulence, and a dual-flavi immune response in mice. J Virol 85: 250313.
  • 23
    Chang G.J.J., Hunt A.R., Holmes D.A., Springfield T., Chiueh T.S., Roehrig J.T., Gubler D.J. ( 2003) Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue type 2 and Japanese encephalitis virus. Virology 306: 17080.
  • 24
    Chambers T.J., Jiang X., Droll D.A., Liang Y., Wold W.S.M., Nickels J. ( 2006) Chimeric Japanese encephalitis virus/dengue 2 virus infectious clone: biological properties, immunogenicity and protection against dengue encephalistis in mice. J Virol 87: 313140.
  • 25
    Heinz F.X., Stiasny K. ( 2012) Flavivirus and their antigenic structure. J Clin Virol 55: 28995.
  • 26
    Mansfield K.L., Horton D.L., Johnson N., Li L., Barrett A.D.T., Smith D.J., Galbraith S.E., Solomon T., Fooks A.R. ( 2011) Flavivirus-induced antibody cross-reactivity. J Virol 92: 282129.
  • 27
    Lobigs M., Diamond M.S. ( 2011) Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex. Expert Rev Vaccines 11: 17787.
  • 28
    Putvana S., Yokasan S., Chayyodin T., Bhamarapravati N., Halstead S.B. ( 1984) Absence of dengue 2 infection enhancement in human sera containing Japanese encephalitis antibodies. Am J Trop Med Hyg 33: 28894.
  • 29
    Anderson K.B., Gibbons R.V., Thomas R.J., Rothman A.L., Nisalak A., Berkelman R.L., Libraty D.H., Endy T.P. ( 2011) Preexisting Japanese encephalitis virus neutralizing antibodies and increased symptomatic dengue illness in a school-based cohort in Thailand. PLoS Negl Trop Dis 5: e1311.
  • 30
    Konishi E., Terazawa A., Fujii A. ( 2003) Evidence for antigen production in muscles by dengue and Japanese encephalitis DNA vaccines and relation to their immunogenicity in mice. Vaccine 21: 371320.
  • 31
    Konishi E., Kosugi S., Imoto J. ( 2006) Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 24: 22007.
  • 32
    Konishi E., Fujii A. ( 2002) Dengue type 2 virus subviral extracellullar particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. Vaccine 20: 105867.
  • 33
    Yamanaka A., Kosugi S., Konishi E. ( 2008) Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. J Virol 82: 92737.
  • 34
    Konishi E., Tabuchi Y., Yamanaka A. ( 2010) A simple assay system for infection-enhancing and -neutralizing antibodies to dengue type 2 virus using layers of semi-adherent K562 cells. J Virol Methods 163: 3607.
  • 35
    Kuwahara M., Konishi E. ( 2010) Evaluation of extracellular subviral particles of dengue virus type 2 and Japanese encephalitis virus produced by Spodoptera frugiperda cells for use as vaccine and diagnostic antigens. Clin Vaccine Immunol 17: 15606.
  • 36
    Serafin I.L., Aaskov J.G. ( 2001) Identification of epitopes on the envelope (E) protein dengue 2 and dengue 3 viruses using monoclonal antibodies. Arch Virol 146: 246979.
  • 37
    Mehlhop E., Ansarah-Robinho C., Jhonson S., Engle M., Freemont D.H., Pierson T.C., Diamond M.S. ( 2007) Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbes 2: 41726.
  • 38
    Tang W.F., Eshita Y., Tadano M., Morita K., Makino Y. ( 2005) Molecular basis for adaptation of a chimeric dengue type-4/Japanese encephalitis virus to Vero cells. Microb Immunol 49: 201927.
  • 39
    Caufour P.S., Motta M.C.A., Yamamura A.M., Vasquez S., Ferreira I.I., Jabor A.V., Bonaldo M.C., Freire M.S., Galler R. ( 2001) Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses. Virus Res 79: 114.
  • 40
    Dowd K.A., Pierson T.C. ( 2011) Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology 411: 30611.
  • 41
    Hsieh S.C., Liu I.J., King C.C., Chang G.J., Wang W.K. ( 2008) A strong endoplasmic reticulum retention signal in the stem-anchor region of envelope glycoprotein of dengue virus type 2 affects the production of virus-like particles. Virology 374: 33850.
  • 42
    Hsieh S.C., Tsai W.Y., Kang W.K. ( 2010) The length of and nonhydrophobic residues in the transmembrane domain of dengue virus envelope protein are critical for its retention and assembly in the endoplasmic reticulum. J Virol 84: 472887.
  • 43
    Butrapet S., Childers T., Moss K.J., Erb S.M., Luy B.E., Calvert A.E., Blair C.D., Roehrig J.T., Huang C.Y. ( 2011) Amino acid changes within the E protein hinge region that affect dengue virus type 2 infectivity and fusion. Virology 413: 11827.
  • 44
    Lin S.R., Zou G., Hsieh S.C., Qing M., Tsai W.Y., Shi P.Y., Wang W.K. ( 2011) The helical domains of the stem region of dengue virus envelope protein are involved in both virus assembly and entry. J Virol 85: 515971.
  • 45
    Sukulpovy-Petty S., Austin S.K., Purtha W.E., Oliphant T., Nybakken G.E., Schleisinger J.J., Roehrig J.T., Gromowski G.D., Barrett A.D., Fremont D.H., Diamond M.S. ( 2007) Type- and subcomplex specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 81: 1281626.
  • 46
    Matsui K., Gromowski G.D., Li L., Shuh A.J., Lee J.C., Barrett A.D. ( 2009) Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III. Virology 384: 1620.
  • 47
    Gromowski G.D., Barrett A.D. ( 2007) Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366: 34960.
  • 48
    Beltramello M., Williams K.L., Simmons C.P., Macagno A., Simonelli L., Quyen N.T., Sukulpovi-Petty S., Navarro-Sanchez E., Young P.R., de Silva A.M., Rey F.A., Varani L., Whitehead S.S., Diamond M.S., Harris E., Lanzavecchia A., Sallusto F. ( 2010) The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8: 27183.
  • 49
    Guzman M.G., Hermida L., Bernardo L., Ramirez R., Guillẻn G. ( 2010) Domain III of the envelope protein as a dengue vaccine target. Expert Rev Vaccines 9: 13747.
  • 50
    Chảvez J.H., Silva J.R., Amarilla A.A., Moraes F.L.T. ( 2010) Domain III peptides from flavivirus envelope are useful antigens for serologic diagnosis and targets for immunization. Biologicals 38: 6138.
  • 51
    Izquierdo A., Bernardo L., Martin J., Santana E., Hermida L., Gullẻn G., Guzman M.G. ( 2008) Serotype-specificity of recombinant fusions proteins containing domain III of dengue virus. Virus Res 138: 1358.
  • 52
    Izquierdo A., Valdẻs I., Gil L., Hermida L., Gutiẻrrez S., Garciả A., Bernardo L., Pavón A., Guillẻn G., Guzmản G. ( 2012) Serotype specificity of recombinant fusion protein containing domain III and capsid protein of denge virus 2. Antiviral Res 95: 18.
  • 53
    Gaurav B., Rajendra R., Satinder D., Nehra K., Sathyamangalam S., Nain K. ( 2010) Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neuralizing antibodies. J Virol Methods 167: 106.
  • 54
    Crill W.D., Hughes H.R., Delorey M.J., Chang G.J. ( 2009) Humoral immune response of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS ONE 4: e4991.
  • 55
    Midgley C.M., Bajwa-Joseph M., Vasanawathana S., Limpitkul W., Wills B., Flanagan A., Waiyaiya E., Tran H.B., Cowper A.E., Chotiyarnwong P., Grimes J.M., Yoksan S., Malasit P., Simmons C.P., Mongkolsapaya J., Screaton G.R. ( 2011) An in depth analysis of original antigenic sin in dengue virus infection. J Virol 85: 41021.